UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer

Drug resistance updates, 2021-03, Vol.55, p.100744-100744, Article 100744

2021

Volltextzugriff (PDF)

Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts

British journal of cancer, 2022-01, Vol.126 (1), p.120-128

2022

Volltextzugriff (PDF)

The impact of DNA damage response gene polymorphisms on therapeutic outcomes in late stage ovarian cancer

Scientific reports, 2016-12, Vol.6 (1), p.38142-38142, Article 38142

2016

Volltextzugriff (PDF)

Correction to: Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts

British journal of cancer, 2023-03, Vol.128 (7), p.1405-1405

2023

Volltextzugriff (PDF)

Inhibition of Chk1 and Wee1 as an effective therapeutic approach in diffuse large B cell lymphomas: A way to target Myc?

European journal of cancer (1990), 2016-12, Vol.69, p.S122-S122

2016

Volltextzugriff (PDF)

Ovarian cancer patient-derived xenografts resistant to cisplatin exhibit metabolic changes

European journal of cancer (1990), 2016-07, Vol.61, p.S46-S47

2016

Volltextzugriff (PDF)

Genetic instability influences drug response in cancer cells

Current drug targets, 2010-10, Vol.11 (10), p.1317-1324

2010

Volltextzugriff (PDF)

Role of homologous recombination in trabectedin-induced DNA damage

European journal of cancer (1990), 2008-03, Vol.44 (4), p.609-618

2008

Volltextzugriff (PDF)

Expression of DNA repair genes in ovarian cancer samples: Biological and clinical considerations

European journal of cancer (1990), 2011-05, Vol.47 (7), p.1086-1094

2011

Volltextzugriff (PDF)

Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action

European journal of cancer (1990), 2001, Vol.37 (1), p.97-105

2001

Volltextzugriff (PDF)

PO-040 Characterisation of CDK12 knocked out ovarian cancer cell lines

ESMO open, 2018-07, Vol.3 (Suppl 2), p.A36-A36

2018

Volltextzugriff (PDF)

A High-throughput Screening of a Chemical Compound Library in Ovarian Cancer Stem Cells

Combinatorial chemistry & high throughput screening, 2018-01, Vol.21 (1), p.50-56

2018

Volltextzugriff (PDF)

601: Cisplatin response in a panel of patient-derived ovarian carcinoma xenografts: roles of epithelial mesenchymal transition and DNA repair

European journal of cancer (1990), 2014-07, Vol.50, p.S145-S145

2014

Volltextzugriff (PDF)

340 Preclinical activity of the VEGFR, FGFR and PDGFR inhibitor lucitanib in FGFR2 aberrant endometrial and gastric cancer models

European journal of cancer (1990), 2014-11, Vol.50, p.110-110

2014

Volltextzugriff (PDF)

Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents

International journal of cancer, 2012-07, Vol.131 (1), p.59-69

2012

Volltextzugriff (PDF)

PO-473 Quantification of ERCC1-XPF complexes in ovarian cancer xenografts with different sensitivity to cisplatin

ESMO open, 2018-07, Vol.3 (Suppl 2), p.A208-A208

2018

Volltextzugriff (PDF)

767 Ovarian Carcinoma Xenografts – Drug Response and Molecular Characterization

European journal of cancer (1990), 2012-07, Vol.48, p.S182-S182

2012

Volltextzugriff (PDF)

Histone demethylating agents as potential S -adenosyl- l -methionine-competitors

MedChemComm, 2016-01, Vol.7 (6), p.1245-1255

2016

Volltextzugriff (PDF)

Molecular targeting: new therapeutic strategies to improve tumour apoptosis

Annals of oncology, 2004-01, Vol.15 (suppl-4), p.iv229-iv231

2004

Volltextzugriff (PDF)

Improving responses to dual PI3K/BCL2 inhibition in lymphomas: results of a pharmacological screen with over 1,400 compounds

European journal of cancer (1990), 2022-10, Vol.174, p.S107-S108

2022

Volltextzugriff (PDF)

Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines

European journal of cancer (1990), 1998-10, Vol.34 (11), p.1783-1788

1998

Volltextzugriff (PDF)

370 - Inhibition of Chk1 and Wee1 as an effective therapeutic approach in diffuse large B cell lymphomas: A way to target Myc?

European journal of cancer (1990), 2016-12, Vol.69, p.S122-S122

2016

Volltextzugriff (PDF)

329 - Exosomes/EVs: STRATEGIES TOWARD CLINICAL TRANSLATION OF EXTRACELLULAR VESICLES FROM HUMAN INDUCED PLURIPOTENT STEM CELLS

Cytotherapy (Oxford, England), 2023-05, Vol.25 (6), p.S114-S115

2023

Volltextzugriff (PDF)

Exosomes/EVs: STRATEGIES TOWARD CLINICAL TRANSLATION OF EXTRACELLULAR VESICLES FROM HUMAN INDUCED PLURIPOTENT STEM CELLS

Cytotherapy (Oxford, England), 2023-05, Vol.25 (6), p.S114-S115

2023

Volltextzugriff (PDF)

251 - Ovarian cancer patient-derived xenografts resistant to cisplatin exhibit metabolic changes

European journal of cancer (1990), 2016-07, Vol.61, p.S46-S47

2016

Volltextzugriff (PDF)

1 – 25 von 416

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(310)
Mit Volltextzugriff
(293)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer

Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts

The impact of DNA damage response gene polymorphisms on therapeutic outcomes in late stage ovarian cancer

Correction to: Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts

Inhibition of Chk1 and Wee1 as an effective therapeutic approach in diffuse large B cell lymphomas: A way to target Myc?

Ovarian cancer patient-derived xenografts resistant to cisplatin exhibit metabolic changes

Genetic instability influences drug response in cancer cells

Role of homologous recombination in trabectedin-induced DNA damage

Expression of DNA repair genes in ovarian cancer samples: Biological and clinical considerations

Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action

PO-040 Characterisation of CDK12 knocked out ovarian cancer cell lines

A High-throughput Screening of a Chemical Compound Library in Ovarian Cancer Stem Cells

601: Cisplatin response in a panel of patient-derived ovarian carcinoma xenografts: roles of epithelial mesenchymal transition and DNA repair

340 Preclinical activity of the VEGFR, FGFR and PDGFR inhibitor lucitanib in FGFR2 aberrant endometrial and gastric cancer models

Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents

PO-473 Quantification of ERCC1-XPF complexes in ovarian cancer xenografts with different sensitivity to cisplatin

767 Ovarian Carcinoma Xenografts – Drug Response and Molecular Characterization

Histone demethylating agents as potential S -adenosyl- l -methionine-competitors

Molecular targeting: new therapeutic strategies to improve tumour apoptosis

Improving responses to dual PI3K/BCL2 inhibition in lymphomas: results of a pharmacological screen with over 1,400 compounds

Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines

370 - Inhibition of Chk1 and Wee1 as an effective therapeutic approach in diffuse large B cell lymphomas: A way to target Myc?

329 - Exosomes/EVs: STRATEGIES TOWARD CLINICAL TRANSLATION OF EXTRACELLULAR VESICLES FROM HUMAN INDUCED PLURIPOTENT STEM CELLS

Exosomes/EVs: STRATEGIES TOWARD CLINICAL TRANSLATION OF EXTRACELLULAR VESICLES FROM HUMAN INDUCED PLURIPOTENT STEM CELLS

251 - Ovarian cancer patient-derived xenografts resistant to cisplatin exhibit metabolic changes

Suchergebnisse filtern